Compassionate Use of SOM230 for Hyperinsulinemic/Hypoglycemia

Status No longer available

Clinical Trial Summary

Congenital hyperinsulinism is a rare condition that can cause life-threatening hypoglycemia. Current treatment for congenital hyperinsulinism is often suboptimal, and such individuals may respond to a new somatostatin analog, pasireotide. This is a compassionate use study of the effects of pasireotide on individuals with suboptimally treated congenital hyperinsulinism.

Clinical Trial Description

Congenital hyperinsulinism is a rare condition that can cause life-threatening hypoglycemia. Current treatment for congenital hyperinsulinism is often suboptimal, with diazoxide as the mainstay of treatment. Individuals who are not adequately treated with diazoxide may undergo pancreatectomy. Octreotide has been used with some success in congenital hyperinsulinism but there is limited data on pasireotide, the newest somatostatin receptor agonist, which, compared to octreotide, has 30-40 times greater affinity for somatostatin receptors 1 (SSTR1) and 5 (SSTR5), 5 times greater for somatostatin receptor 3 (SSTR3) and a comparable affinity for somatostatin receptor 2 (SSTR2). In human islets, SSTR2 & SSTR5 are present in beta cells. Therefore, there is reason to believe that pasireotide may have greater effectiveness than octreotide in preventing hypoglycemia due to hyperinsulinism. Indeed hyperglycemia is a known effect of pasireotide when used for treatment of Cushing's disease and Acromegaly. The current study is of compassionate use for prevention of hypoglycemia in individuals with congenital hyperinsulinemic hypoglycemia who are not adequately treated with diazoxide. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02835131
Study type	Expanded Access
Source	Montefiore Medical Center
Contact
Status	No longer available
Phase

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02021604` - Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma	Phase 1
Recruiting	`NCT04732416` - HM15136 Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)	Phase 2
Completed	`NCT02937558` - CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism	Phase 2
Completed	`NCT02604485` - A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism	Phase 2
Recruiting	`NCT04205604` - 18FluoroLDOPA PET Imaging for the Detection and Localization of Focal Congenital Hyperinsulinism	Phase 2
Completed	`NCT00987168` - Sandostatine® LP and Hyperinsulinism	Phase 2
Completed	`NCT00897676` - Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity	Phase 1/Phase 2
Active, not recruiting	`NCT03941236` - Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism	Phase 3
Completed	`NCT03042416` - 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety	Phase 3
Completed	`NCT04172441` - Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism	Phase 2/Phase 3
Recruiting	`NCT04706910` - 18F-DOPA II - PET Imaging Optimization	Phase 3
Recruiting	`NCT06208215` - RZ358 Treatment for Congenital Hyperinsulinism	Phase 3
Completed	`NCT03777176` - A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism	Phase 3
Recruiting	`NCT03768518` - GLP-1 Receptor Expression in CHI
Completed	`NCT04538989` - An Open-Label Multiple Dose Study of RZ358 in Patients With Congenital Hyperinsulinism	Phase 2
Completed	`NCT01070758` - Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy	Phase 4
Completed	`NCT00674440` - Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism	Phase 2
Terminated	`NCT00835328` - Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia	Phase 1/Phase 2
Completed	`NCT00571324` - Effect of Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism	Phase 1/Phase 2
Withdrawn	`NCT03053284` - Pasireotide in Hyperinsulinemic Hypoglycemia	Phase 2